Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Werewolf Therapeutics (HOWL) presented interim Phase 1 clinical trial results for WTX-330, their tumor-activated IL-12 prodrug, at SITC's 39th Annual Meeting. The trial enrolled 25 patients with diverse solid tumors, showing favorable tolerability and encouraging efficacy. Key findings include a confirmed partial response in a melanoma patient and evidence of tumor immune activation in MSS CRC patients. WTX-330 demonstrated 22-fold greater plasma exposure compared to rhIL-12, with low active IL-12 levels. The company plans to initiate a Phase 1/2 dose-finding trial in H1 2025. Additional preclinical data showed promising results for INDUKINE molecules with various cytokines.
Werewolf Therapeutics (HOWL) ha presentato risultati intermedi della fase 1 dello studio clinico per WTX-330, il loro pro-farmaco IL-12 attivato dai tumori, durante il 39° incontro annuale della SITC. Lo studio ha arruolato 25 pazienti con tumori solidi diversi, mostrando una tollerabilità favorevole e un'efficacia incoraggiante. I risultati chiave includono una risposta parziale confermata in un paziente con melanoma e prove di attivazione immunitaria tumorale in pazienti con CRC MSS. WTX-330 ha dimostrato una maggiore esposizione plasmatica di 22 volte rispetto all'rhIL-12, con bassi livelli di IL-12 attivo. L'azienda prevede di avviare uno studio di fase 1/2 per la ricerca di dosi nel primo semestre del 2025. Ulteriori dati preclinici hanno mostrato risultati promettenti per le molecole INDUKINE con vari citochine.
Werewolf Therapeutics (HOWL) presentó resultados intermedios del ensayo clínico de fase 1 para WTX-330, su profármaco de IL-12 activado por tumores, en la 39ª Reunión Anual de SITC. El ensayo incluyó a 25 pacientes con diversos tumores sólidos, mostrando una tolerabilidad favorable y una eficacia alentadora. Los hallazgos clave incluyen una respuesta parcial confirmada en un paciente con melanoma y evidencia de activación inmune tumoral en pacientes con CRC MSS. WTX-330 demostró una exposición plasmática 22 veces mayor en comparación con rhIL-12, con bajos niveles de IL-12 activo. La compañía planea iniciar un ensayo de fase 1/2 para encontrar dosis en la primera mitad de 2025. Datos preclínicos adicionales mostraron resultados prometedores para las moléculas INDUKINE con varias citoquinas.
Werewolf Therapeutics (HOWL)는 SITC의 제39회 연례 회의에서 그들의 종양 활성화 IL-12 전구약물인 WTX-330에 대한 1상 임상 시험 중간 결과를 발표했습니다. 이 시험은 다양한 고형 종양을 가진 25명의 환자를 등록했으며, 유리한 내약성과 고무적인 효능을 보여주었습니다. 주요 발견은 흑색종 환자에서 확인된 부분 반응과 MSS CRC 환자에서의 종양 면역 활성 증거입니다. WTX-330은 rhIL-12에 비해 22배 더 높은 혈장 노출을 보였고, 활성 IL-12 수준은 낮았습니다. 이 회사는 2025년 상반기에 1상/2상 용량 탐색 시험을 시작할 계획입니다. 추가 전임상 데이터는 다양한 사이토킨에 대한 INDUKINE 분자의 유망한 결과를 보여주었습니다.
Werewolf Therapeutics (HOWL) a présenté les résultats intermédiaires de l'essai clinique de phase 1 pour WTX-330, leur pro-médicament IL-12 activé par les tumeurs, lors de la 39ème Réunion Annuelle de la SITC. L'essai a recruté 25 patients présentant divers types de tumeurs solides, montrant une tolérance favorable et une efficacité encourageante. Les résultats clés incluent une réponse partielle confirmée chez un patient atteint de mélanome et des preuves d'activation immunitaire tumorale chez des patients atteints de CRC MSS. WTX-330 a démontré une exposition plasmatique 22 fois supérieure par rapport à rhIL-12, avec de faibles niveaux d'IL-12 actif. L'entreprise prévoit de commencer un essai de phase 1/2 pour la recherche de doses au premier semestre 2025. Des données précliniques supplémentaires ont montré des résultats prometteurs pour les molécules INDUKINE avec divers cytokines.
Werewolf Therapeutics (HOWL) hat beim 39. Jahresmeeting der SITC Zwischenresultate der Phase 1 des klinischen Trials für WTX-330, ihr tumorfunktionales IL-12 Prodrug, vorgestellt. In der Studie wurden 25 Patienten mit verschiedenen soliden Tumoren aufgenommen, die eine günstige Verträglichkeit und ermutigende Wirksamkeit zeigten. Wichtige Erkenntnisse umfassen eine bestätigte partielle Remission bei einem Melanom-Patienten und Beweise für eine Tumorimmunaktivierung bei MSS CRC-Patienten. WTX-330 zeigte eine 22-fache höhere Plasmakonzentration im Vergleich zu rhIL-12, wobei die aktiven IL-12-Spiegel niedrig blieben. Das Unternehmen plant, im ersten Halbjahr 2025 eine Phase 1/2 Dosisfindungsstudie zu starten. Zusätzliche präklinische Daten zeigten vielversprechende Ergebnisse für INDUKINE-Moleküle mit verschiedenen Zytokinen.
- Confirmed partial response achieved in melanoma patient
- WTX-330 showed 22-fold greater plasma exposure vs rhIL-12
- Favorable tolerability profile with manageable adverse events
- Evidence of IL-12 activity in tumor microenvironment
- Most patients (70%) required at least two prior lines of therapy
- Only one confirmed partial response reported among 25 patients
Insights
The interim Phase 1 data for WTX-330 represents a significant milestone in IL-12 based immunotherapy development. The 22-fold greater plasma exposure compared to rhIL-12, while maintaining low active IL-12 levels (<1.6% of prodrug), demonstrates impressive pharmacokinetic improvements. The confirmed partial response in a melanoma patient who previously progressed on pembrolizumab is particularly noteworthy, suggesting potential efficacy in immunotherapy-resistant cases.
The safety profile appears manageable, with mostly mild to moderate adverse events. The evidence of IL-12 activity in tumor biopsies from MSS CRC patients is promising, as microsatellite stable colorectal cancer typically responds poorly to immunotherapy. The planned Phase 1/2 trial expansion in H1 2025 will be important for determining optimal dosing and identifying most responsive tumor types.
The clinical data presented shows meaningful progress in addressing historical challenges with IL-12 therapeutics. The tumor-selective activation approach appears to be working, evidenced by the favorable tolerability despite higher systemic exposure. The immune activation observed in MSS CRC biopsies is particularly significant, as these tumors are traditionally considered "cold" and resistant to immunotherapy.
The preclinical data comparing different cytokine-based INDUKINE molecules (IL-2, IL-12, IL-21, IL-18) provides valuable insights into potential combination strategies and indication selection. The confirmed partial response in a heavily pretreated melanoma patient who failed prior immunotherapy suggests potential utility in both immunotherapy-naive and resistant populations.
- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals -
- Additional preclinical data demonstrate INDUKINETM molecules’ anti-tumor potency with distinct immune activation profiles across four cytokines -
WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune mediated conditions, today shared clinical and preclinical data at the 2024 Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, taking place November 6-10 in Houston, Texas.
WTX-330, a potential first-in-class systemically delivered IL-12 therapy selectively activated in the tumor microenvironment, is currently being evaluated in a Phase 1 clinical trial: NCT05678998. This is Werewolf’s second clinical program to validate the INDUKINE design, delivering potent immune mechanisms to the tumor with improved tolerability and evidence of clinical efficacy. Preliminary clinical findings presented at SITC demonstrate WTX-330’s promising therapeutic potential as a monotherapy, exhibiting a favorable tolerability profile and inducing tumor shrinkage in patients with treatment-resistant solid tumors, including those tumors that are less sensitive to immunotherapy. A Phase 1/2 dose- and regimen-finding clinical trial, designed to optimize WTX-330 exposure in the tumor microenvironment and explore activity in selected indications, is expected to begin enrolling in the first half of 2025.
“The data from this first-in-human trial of WTX-330 combined with the observed monotherapy activity seen in both immunotherapy sensitive and resistant solid tumors in heavily pretreated patients, reinforces our belief in WTX-330's potential to address critical unmet needs in oncology,” said Randi Isaacs, M.D., Chief Medical Officer. “We are excited to advance the development of this novel therapeutic and explore its full clinical potential for the benefit of patients."
As of October 7, 2024, the study had enrolled twenty-five patients with diverse solid tumors, including microsatellite stable colorectal cancer (MSS CRC), cholangiocarcinoma, metastatic cutaneous melanoma, and non-small cell lung cancer (NSCLC), with more than
- Favorable tolerability profile: Treatment-related adverse events (AEs) were primarily mild to moderate (most commonly fatigue, increased aspartate transaminase/alanine transaminase (AST/ALT), pyrexia, and neutropenia); severe AEs occurred but were manageable and reversible.
- Pharmacokinetic improvements over rhIL-12: WTX-330 had 22-fold greater plasma exposure than the reported maximum tolerated dose of rhIL-12 but with low levels of active IL-12 (<
1.6% of prodrug). - IL-12 activity and tumor immune activation: Evidence of IL-12 activity in the tumor microenvironment with four patients with MSS CRC showing evidence of tumor immune activation in on-treatment tumor biopsies .
- Antitumor activity: A 76 year old patient with diffuse in-transit metastatic melanoma who had progressed on adjuvant pembrolizumab achieved a Response Evaluation Criteria in Solid Tumors (RECIST) confirmed partial response.
Additionally, Werewolf presented preclinical data demonstrating the ability of INDUKINE molecules containing IL-2, IL-12, IL-21, or IL-18 cytokines to generate cytokine-specific antitumor immunity as monotherapy in mice bearing syngeneic tumors. These data revealed unique pharmacological profiles for each cytokine, underscoring the strategic rationale to develop each as an INDUKINE molecule for targeted therapeutic applications.
About WTX-330
WTX-330 was designed to be a systemically dosed prodrug with the ability to deliver fully active IL-12 selectively into the tumor microenvironment via targeted intratumoral activation of the INDUKINE molecule, potentially broadening the therapeutic window and promoting local activation and immune response against the tumor.
About Werewolf Therapeutics
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit www.werewolftx.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Werewolf’s strategy, future operations, prospects, plans, and objectives of management; the expected timeline for the preclinical and clinical development of product candidates, and the availability of data from such preclinical and clinical development; the potential activity and efficacy of product candidates in preclinical studies and clinical trials; the anticipated safety profile of product candidates; and the upcoming presentations at SITC, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “approach,” “believe,” “contemplate,” “continue,” “could,” “design,” “designed to,” “engineered,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “promise,” “should,” “target,” “will,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the development of product candidates, including the conduct of research activities and the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and the Company’s ability to submit and obtain regulatory approval for investigational new drug applications; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; whether preliminary or interim data from a clinical trial will be predictive of the results of the trial and future clinical trials; the Company’s ability to manage cash resources and obtain additional cash resources to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in the “Risk Factors” section of the Company’s most recent Form 10-Q filed with the Securities and Exchange Commission (“SEC”), and in subsequent filings the Company may make with the SEC. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.
Investor Contact:
John Norton
Precision AQ
212.362.1200
John.Norton@precisionaq.com
Media Contact:
Amanda Sellers
Deerfield Group
301.332.5574
amanda.sellers@deerfieldgroup.com
Company Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com
FAQ
What were the key results from Werewolf Therapeutics (HOWL) WTX-330 Phase 1 trial?
When will Werewolf Therapeutics (HOWL) begin Phase 1/2 dose-finding trial for WTX-330?